SCHEMBL25324271

SCHEMBL25324271

CNC(=O)c1ccc(C2CCN(C(=O)OC(C)(C)C)CC2)c(F)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.49
CNR1 P21554 1/20 0.49
TRPV3 Q8NET8 2/20 0.46
ALDH1A1 P00352 2/20 0.45
LMNA P02545 2/20 0.45
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
GPR119 Q8TDV5 3/20 0.44
JAK2 O60674 2/20 0.44
JAK3 P52333 2/20 0.44
PTK2 Q05397 1/20 0.44
KDM4E B2RXH2 2/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
PTPN2 P17706 1/20 0.43
PTPN1 P18031 1/20 0.43
PTPN6 P29350 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31097541 1.00 CNR2 (0.49) CNR2CNR1TRPV3ALDH1A1LMNA
SCHEMBL27202748 0.88 CNR2 (0.47) CNR2CNR1LMNAGPR119JAK2
SCHEMBL30849193 0.88 CNR2 (0.49) CNR2CNR1TRPV3ALDH1A1LMNA
SCHEMBL29148539 0.88 CNR2 (0.49) CNR2CNR1TRPV3ALDH1A1LMNA
SCHEMBL13132432 0.83 GPR119 (0.50) CNR2CNR1TRPV3GPR119KDM4E
SCHEMBL21245809 0.82 ALOX5AP (0.50) CNR2CNR1TRPV3GPR119KDM4E
SCHEMBL29790202 0.81 BACE1 (0.53) MAPTKMT2A
SCHEMBL22912768 0.81 BACE1 (0.53) MAPTKMT2A
SCHEMBL31487235 0.79 GPR119 (0.45) TRPV3GPR119
SCHEMBL30849217 0.79 USP30 (0.48) ALDH1A1GPR119MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171418-A1 PARP1 INHIBITORS AND USES THEREOF XINTHERA, INC. 2025-05-29 US disclosed
EP-4460497-A1 PARP1 INHIBITORS AND USES THEREOF Xinthera, Inc. (US) 2024-11-13 EP disclosed
CN-117447449-A PARP1 inhibitor and application thereof 南京圣和药业股份有限公司 2024-01-26 CN disclosed
WO-2023146960-A1 PARP1 INHIBITORS AND USES THEREOF XINTHERA, INC. (US) 2023-08-03 WO disclosed
WO-2023146960-A1 PARP1 INHIBITORS AND USES THEREOF XINTHERA, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171418-A1 PARP1 INHIBITORS AND USES THEREOF PARP1, PARP11, PARP12 CNR2 4033/4885CNR1 3765/4885TRPV3 4547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.